EUVIMEDEUVIMED entdecken
Kontrollierte klinische StudieMultizentrische StudieOpen Access · CC BY 4.0

Paroxysmal atrial fibrillation ablation with a novel temperature‐controlled CF‐sensing catheter: Q‐FFICIENCY clinical and healthcare utilization benefits

Ayman A Hussein iD, M Craig Delaughter, George Monir iD, Andrea Natale iD, Srinivas Dukkipati, Saumil Oza, Emile Daoud iD, Luigi Di Biase iD, Moussa Mansour, Robert Fishel, Miguel Valderrabano, Kenneth Ellenbogen iD und 2 weitere

Journal of Cardiovascular Electrophysiology · 2023

DOI: 10.1111/jce.16093 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2023. Verfasst von Ayman A Hussein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Foundation, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pulmonary Veins, Catheter Ablation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biosense Webster, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prospective, nonrandomized, multicenter Q‐FFICIENCY study demonstrated the safety and 12‐month efficacy of paroxysmal atrial fibrillation (AF) ablation with the novel QDOT MICRO temperature‐controlled, contact force‐sensing, radiofrequency (RF) catheter. Participants underwent pulmonary vein isolation with very high‐power short‐duration (vHPSD) mode (90 W, ≤4 s) alone or combined with conventional‐power temperature‐controlled (CPTC) mode (25–50 W). This study aimed to assess quality‐of‐life (QOL) and healthcare utilization (HCU) benefits experienced by Q‐FFICIENCY study participants.

Methods

Besides evaluating procedural efficiency, QOL and HCU were assessed through 12 months postablation via Atrial Fibrillation Effect on Quality‐of‐Life Tool (AFEQT) score, antiarrhythmic drug (AAD) use, and incidence of cardioversion and cardiovascular hospitalization.

Results

Of 191 participants enrolled, 166 were ablated with the new catheter. Compared to baseline, statistically significant, clinically meaningful improvements in composite and subcategories of AFEQT scores were observed at 3 months and sustained through 12 months (12‐month increase, 29.3–44.2 points). Class I/III AAD use decreased from 97.6% (162/166) at baseline to 19.6% (31/158) during Months 6–12, representing a significant 79.9% reduction. The cardioversion rate significantly declined by 93.9% from 31.3% (12 months preablation) to 1.9% (evaluation period). One‐year Kaplan–Meier estimates of freedom from all‐cause and cardiovascular hospitalization were 80.9% (95% confidence interval [CI], 74.8%–86.9%) and 88.8% (95% CI, 84.0%–93.7%), respectively.

Conclusions

Paroxysmal AF ablation with the novel temperature‐controlled RF catheter in vHPSD mode, alone or with CPTC mode, led to clinically meaningful improvement in QOL and significant reduction in AAD use, cardioversion, and cardiovascular hospitalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPulmonary VeinsCatheter AblationHumansProspective StudiesQuality of LifeTemperatureTreatment OutcomeCathetersAnti-Arrhythmia AgentsPatient Acceptance of Health Care

Stichwörter der Autor:innen

QDOT MICROQMODE+healthcare utilizationquality of lifetemperature-controlled ablationvery high-power short-duration

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Texas Health Heart & Vascular, Arlington, Texas, USA.
  • AdventHealth Orlando, Orlando, Florida, USA.
  • Texas Cardiac Arrhythmia Institute, Austin, Texas, USA.
  • Mount Sinai School of Medicine, New York, New York, USA.
  • St. Vincent's Medical Center, Jacksonville, Florida, USA.

ORCID-Profile: Ayman A Hussein, George Monir, Andrea Natale, Emile Daoud, Luigi Di Biase, Kenneth Ellenbogen

Förderung

  • Biosense Webster, Inc.

Zitieren

APA

Hussein, A. A., Delaughter, M. C., Monir, G., Natale, A., Dukkipati, S., Oza, S., Daoud, E., Di Biase, L., Mansour, M., Fishel, R., Valderrabano, M., Ellenbogen, K., Osorio, J., & Q-FFICIENCY investigators (2023). Paroxysmal atrial fibrillation ablation with a novel temperature‐controlled CF‐sensing catheter: Q‐FFICIENCY clinical and healthcare utilization benefits. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16093

Vancouver

Hussein AA, Delaughter MC, Monir G, Natale A, Dukkipati S, Oza S, et al. Paroxysmal atrial fibrillation ablation with a novel temperature‐controlled CF‐sensing catheter: Q‐FFICIENCY clinical and healthcare utilization benefits. Journal of Cardiovascular Electrophysiology. 2023. doi:10.1111/jce.16093

BibTeX
@article{Hussein2023,
  author = {Hussein, Ayman A and Delaughter, M Craig and Monir, George and Natale, Andrea and Dukkipati, Srinivas and Oza, Saumil and Daoud, Emile and Di Biase, Luigi and Mansour, Moussa and Fishel, Robert and Valderrabano, Miguel and Ellenbogen, Kenneth and Osorio, Jose and Q-FFICIENCY investigators, Q-FFICIENCY investigators},
  title = {Paroxysmal atrial fibrillation ablation with a novel temperature‐controlled CF‐sensing catheter: Q‐FFICIENCY clinical and healthcare utilization benefits},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2023},
  doi = {10.1111/jce.16093}
}
Kostenlos starten →